Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free PXMD Stock Alerts

PaxMedica (PXMD) Competitors

PaxMedica logo
$0.0005 0.00 (0.00%)
As of 08/13/2026
Compare

PXMD vs. CLVR, SCPS, NAVB, GNCA, and ARDS

Should you buy PaxMedica stock or one of its competitors? PaxMedica's main competitors and comparable companies include Clever Leaves (CLVR), Scopus BioPharma (SCPS), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), and Aridis Pharmaceuticals (ARDS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PaxMedica compare to Clever Leaves?

PaxMedica (NASDAQ:PXMD) and Clever Leaves (NASDAQ:CLVR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Clever Leaves has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Clever Leaves' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Clever Leaves N/A N/A N/A

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, meaning that its share price is 381,513% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Clever Leaves Neutral

Summary

Clever Leaves beats PaxMedica on 8 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
PaxMedica Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

Scopus BioPharma's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

4.9% of PaxMedica shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Scopus BioPharma beats PaxMedica on 5 of the 6 factors compared between the two stocks.

How does PaxMedica compare to Navidea Biopharmaceuticals?

PaxMedica (NASDAQ:PXMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Navidea Biopharmaceuticals Neutral

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Navidea Biopharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Genocea Biosciences?

PaxMedica (NASDAQ:PXMD) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Genocea Biosciences' return on equity of -182.88% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Genocea Biosciences N/A -182.88%-62.76%

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Genocea Biosciences Neutral

PaxMedica has higher earnings, but lower revenue than Genocea Biosciences. PaxMedica is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Summary

Genocea Biosciences beats PaxMedica on 6 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Aridis Pharmaceuticals has a beta of 49.62, indicating that its share price is 4,862% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
PaxMedica Neutral

PaxMedica is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
PaxMedicaN/AN/A-$18.29M-$6.09N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

Summary

Aridis Pharmaceuticals beats PaxMedica on 7 of the 8 factors compared between the two stocks.

Get PaxMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PXMD vs. The Competition

Export
MetricPaxMedicaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6K$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio0.00775.15269.0625.28
Price / SalesN/A741.16592.9687.71
Price / CashN/A66.4570.4850.90
Price / Book0.0011.6012.916.24
Net Income-$18.29M$2.77B$3.45B$347.60M
7 Day PerformanceN/A0.17%1.12%1.07%
1 Month PerformanceN/A0.35%1.79%1.03%
1 Year PerformanceN/A161.52%67.69%20.77%

PaxMedica Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A2
CLVR
Clever Leaves
N/A$0.01
flat		N/A-50.0%$18K$17.42MN/A560
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A+33.3%$17KN/AN/A9
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PXMD) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel